BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9365622)

  • 1. Experience with new cyclosporine formulations: Consupren and Neoral in renal transplant patients.
    Barbari A; Stephan A; Kamel G; Kilany H; Masri MA
    Transplant Proc; 1997 Nov; 29(7):2941-4. PubMed ID: 9365622
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
    Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
    Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
    Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
    Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 6. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
    [No Abstract]   [Full Text] [Related]  

  • 7. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients.
    Stephan A; Masri MA; Barbari A; Aoun S; Rizk S; Kamel G
    Transplant Proc; 1998 Nov; 30(7):3533-4. PubMed ID: 9838547
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
    Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
    Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoplanta as a new microemulsion formula of cyclosporine in renal transplantation: comparative study with Neoral for efficacy and safety.
    Kim SC; Han DJ
    Transplant Proc; 1998 Nov; 30(7):3547-8. PubMed ID: 9838552
    [No Abstract]   [Full Text] [Related]  

  • 10. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
    Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
    Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
    [No Abstract]   [Full Text] [Related]  

  • 11. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
    Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract]   [Full Text] [Related]  

  • 12. Lessons from the Neoral Global Database.
    Helderman JH
    Transplant Proc; 1998 Aug; 30(5):1721-2. PubMed ID: 9723255
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and tolerability of Neoral in transplant recipients.
    Feutren G; Wong R; Jin J; Niese D; Mellein B
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients.
    Stephan AG; Barbari A; Masri MA; Rizk S; Moubarak R; Frem GJ; Kamel G; Baracat-Khoury W; Karam A
    Transplant Proc; 1996 Jun; 28(3):1348-9. PubMed ID: 8658688
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
    Warrens AN; Salama A; Waters JB; Lechler RI
    Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
    [No Abstract]   [Full Text] [Related]  

  • 16. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients.
    Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
    Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience.
    Goh BL; Jalil R; Koh SN; Chua CT; Tan SY
    Transplant Proc; 1998 Nov; 30(7):3535-6. PubMed ID: 9838548
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
    Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
    Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
    [No Abstract]   [Full Text] [Related]  

  • 19. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.